Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009. Top-line results from the phase 3 studies were previously reported in September 2009. The presentation included data from the EQUIP (OB-302) and CONQUER (OB-303) studies that further supports the safety and efficacy profile of Qnexa.

The additional efficacy data from the EQUIP study that was presented included weight loss by BMI category, on an intent-to-treat, last observation carried forward (ITT-LOCF) basis for full dose Qnexa.

                     Percent Weight Loss (ITT-LOCF)
                     ------------------------------

    Baseline BMI                Placebo             Full Dose Qnexa
    ------------                -------             ---------------
    >35-40                        1.8%                    10.7%
    >40-45                        1.3%                    11.1%
    >45-50                        1.0%                    11.8%
    >50                           2.0%                    10.3%

"The EQUIP study was designed to look at the effect of Qnexa on morbidly obese patients, that is, those patients with a baseline BMI of 35 or greater. The average baseline BMI in the EQUIP study was 42.1. A review of results by baseline BMI show a consistent effect across a broad range of patients based on starting body weight," stated Wesley W. Day. "On an ITT-LOCF basis,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... 2014 A new report by ... type, Form, End user, Application and Geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", considers ... on key trends tracked, it is anticipated that the ... by 2020, registering a CAGR of 6.2% from 2014 ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... Patients with ADD/ADHD -- NESS ZIONA, Israel, November 9, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... 9, 2010 Alere Inc. (NYSE: ALR ), ... their health at home through the merger of rapid diagnostics ... Lazard Capital Markets 7th Annual Healthcare Conference being held November ...  Jon Russell, Vice President, Finance, will attend.  Mr. Russell,s presentation ...
Cached Medicine Technology:NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 2NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 3NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 4NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 5NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 6NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 7NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD 8
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
(Date:10/20/2014)... With a mere 19 days to November ... brief fundraising stop at the  Law Offices of ... a debate last night with his opponent Gov. Rick ... first seven minutes because Crist had an electric fan ... in one word: "weird." , Before touching on his ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... , SCHAFFHAUSEN, Switzerland, Nov. 30 Tyco ... its 2010 annual general meeting of shareholders will be held ... time at the Park Hyatt Zurich Hotel, Beethoven-Strasse 21, 8002 ... record date) will be entitled to vote at the annual ...
... tiny period of time between the registration of a visual stimulus ... between the time we see an apple and the time we ... but by how long? And how does this affect our reactions ... the time delay lasts only 100 milliseconds, others say 500 milliseconds. ...
... in animals , MONDAY, Nov. 30 (HealthDay News) -- Two ... human-derived umbilical cord blood could help treat some lung and ... cells can differentiate into a long list of different kinds ... the Samsung Medical Center in Seoul, Korea, co-author of one ...
... N.J., Nov. 30 Kemin Foods, L.C. ("Kemin") and ... ("OmniActive") have reached an amicable settlement of their dispute. ... ("the ,714 patent") titled "Process for Isolation, Purification and ... Thereof" and the reissues of that patent are valid ...
... , NASHVILLE, Tenn., Nov. 30 During this time ... a loved one with Alzheimer,s disease or other form of dementia, ... Brookdale Senior Living , one of the leading providers of ... care , offers these suggestions. , A listening device with ...
... Europa Uomo, the European,advocacy movement for the fight ... as part of their long-term commitment to increase ... urological diseases. Professor Per-Anders Abrahamsson, Secretary-General of the ... Uomo will gain access to the latest information ...
Cached Medicine News:Health News:Now you see it, now you know you see it 2Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2
Curved osteotome for bone removing....
... new Spectral system is a combination Spectral ... Ophthalmoscope (SLO) system that provides suberb, high-quality ... structure. With the advancements of spectral technology, ... up to 27,000 A-Scans per second and ...
... The SC is an ... cardiology loads, with the ability ... studies, spot views, Myocardial perfusion ... offering a low cost and ...
... intended for: embolization of those intracranial aneurysms ... or the patient's general medical condition - ... be a) very high risk for management ... GDC is also intended for embolization of ...
Medicine Products: